Key Events This Week
2 Feb: Quality grade downgraded to Below Average, Strong Sell rating assigned
2 Feb: Valuation metrics escalated, stock classified as very expensive
2 Feb: Stock price surged 10.06% despite Sensex decline
3-6 Feb: Mixed daily price movements with overall weekly gain of 21.01%

Hindustan Bio Sciences Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Expensive Valuation
2026-02-02 08:19:59Hindustan Bio Sciences Ltd has been assigned a Strong Sell rating with a Mojo Score of 21.0, reflecting significant concerns across quality, valuation, financial trends, and technical indicators. The downgrade from a previously ungraded status follows a comprehensive reassessment revealing deteriorating fundamentals, expensive market valuation, and mixed technical signals despite recent price gains.
Read full news article
Hindustan Bio Sciences Ltd Valuation Shifts Signal Elevated Price Risk
2026-02-02 08:01:09Hindustan Bio Sciences Ltd, a player in the Software Products sector, has seen a marked shift in its valuation parameters, moving from a risky to a very expensive rating. Despite a strong short-term price rally, the company’s elevated price-to-earnings and price-to-book ratios raise questions about its price attractiveness relative to historical averages and peer benchmarks.
Read full news article
Hindustan Bio Sciences Ltd Quality Grade Downgrade Highlights Fundamental Challenges
2026-02-02 08:00:16Hindustan Bio Sciences Ltd has seen its quality grade downgraded from "Does Not Qualify" to "Below Average" as of 1 February 2026, reflecting deteriorations in key business fundamentals. Despite a recent surge in share price, the company’s financial metrics reveal challenges in profitability, capital efficiency, and growth consistency, raising concerns for investors in the Software Products sector.
Read full news article
Hindustan Bio Sciences Q3 FY26: Profitability Returns But Volatility Remains High
2026-01-31 21:01:08Hindustan Bio Sciences Ltd., a micro-cap pharmaceutical company with a market capitalisation of just ₹7.00 crores, posted a net profit of ₹0.08 crores in Q3 FY26 (October-December 2025), marking a sharp recovery from the ₹0.06 crore loss reported in the previous quarter. The stock surged 4.88% to ₹7.09 on February 1, 2026, though it remains 31.30% below its 52-week high of ₹10.32 amid persistent concerns about operational stability and financial sustainability.
Read full news articleWhen is the next results date for Hindustan Bio Sciences Ltd?
2026-01-20 23:16:12The next results date for Hindustan Bio Sciences Ltd is scheduled for January 31, 2026....
Read full news articleWhy is Hind.Bio Science falling/rising?
2025-11-29 00:44:17
Recent Price Movement and Market Context
Hindustan Bio Sciences’ stock price fell by ₹0.20, representing a 3.17% drop as of 08:35 PM on 28 November. This decline marks the continuation of a downward trend, with the stock having lost 6.58% over the past two consecutive trading days. The fall is particularly significant given that the stock has underperformed its sector by 3.72% on the same day, signalling sector-relative weakness.
The stock’s performance over the short and medium term further highlights its struggles. Over the past week, the share price has declined by 8.41%, in stark contrast to the Sensex’s modest gain of 0.56%. Similarly, the one-month return shows a 6.15% loss for Hindustan Bio Sciences, while the Sensex advanced by 1.27%. These figures underscore t...
Read full news articleWhy is Hind.Bio Science falling/rising?
2025-11-18 22:20:36As of 18-Nov, Hindustan Bio Sciences Ltd is experiencing a decline in its stock price, currently at Rs 6.59, which represents a decrease of -0.34 or -4.91%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total decline of -9.6% during this period. Additionally, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The stock is also close to its 52-week low, just 1.37% away from Rs 6.5. Notably, investor participation has decreased significantly, with delivery volume dropping by -75.16% compared to the 5-day average, indicating a lack of interest among investors. In the broader market context, Hindustan Bio Sciences Ltd has underperformed relative to the benchmark Sensex, which has gained +0.96% over the past week while the stock has declined by -8.34%. Over the past month, the stock has decrease...
Read full news article





